store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Uridine triacetate (RG 2133 triacetate) 是一种具有口服活性的 Uridine 前药。Uridine triacetate 能在肠道内迅速被吸收,在循环中迅速脱乙酰,生成游离尿苷。Uridine triacetate 可用于研究 5-氟尿嘧啶 (5-FU) 和卡培他滨的毒性,或早发性心脏或中枢神经系统 (CNS) 毒性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 123 | 现货 | ||
100 mg | ¥ 163 | 现货 | ||
200 mg | ¥ 226 | 现货 | ||
500 mg | ¥ 359 | 现货 | ||
1 g | ¥ 518 | 现货 | ||
5 g | ¥ 1,260 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 179 | 现货 |
产品描述 | Uridine triacetate (RG 2133 triacetate) (Tri-O-acetyl uridine), an orally active prodrug of uridine, is efficiently absorbed in the gut and swiftly deacetylated in the circulation to release free uridine. It is utilized in the research of 5-fluorouracil (5-FU) and capecitabine toxicity, particularly targeting early-onset cardiac or central nervous system (CNS) complications. |
体外活性 | Uridine triacetate inhibits [3H]uridine uptake in ENT1 and ENT2 overexpressed HeLa cells, with IC50s of 28.4 μM and 228.4 μM respectively[4]. |
体内活性 | Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced toxicity in 5-FU overdose mice. Uridine triacetate (2 g/kg, oral gavage, every 8 h for 15 total doses) improves survival and reduced 5-FU toxicity in DPD deficiency mice[3]. |
别名 | RG 2133 triacetate, PN-401, Tri-O-acetyluridine, PN401, RG 2133, RG-2133, PN 401, RG2133, RG2133 triacetate |
分子量 | 370.31 |
分子式 | C15H18N2O9 |
CAS No. | 4105-38-8 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 90mg/mL (243mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7004 mL | 13.5022 mL | 27.0044 mL | 67.511 mL |
5 mM | 0.5401 mL | 2.7004 mL | 5.4009 mL | 13.5022 mL | |
10 mM | 0.27 mL | 1.3502 mL | 2.7004 mL | 6.7511 mL | |
20 mM | 0.135 mL | 0.6751 mL | 1.3502 mL | 3.3756 mL | |
50 mM | 0.054 mL | 0.27 mL | 0.5401 mL | 1.3502 mL | |
100 mM | 0.027 mL | 0.135 mL | 0.27 mL | 0.6751 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Uridine triacetate 4105-38-8 Others RG 2133 triacetate PN-401 Tri-O-acetyluridine PN401 RG 2133 Triacetate RG 2133 Uridine Triacetate RG2133 Triacetate Uridine RG-2133 Triacetate RG-2133 PN 401 RG2133 RG2133 triacetate Inhibitor inhibitor inhibit